Breaking News, Collaborations & Alliances

Schering-Plough, Novartis Amend COPD Pact

Schering-Plough and Novartis have amended their global collaboration for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Schering-Plough and Novartis have amended their global collaboration for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Schering-Plough will assume exclusive worldwide rights to develop and commercialize a fixed-dose combination of its inhaled corticosteroid Asmanex (mometasone furoate inhalation powder), and Novartis’ long-acting beta2-adrenergic receptor agonist, Foradil (formoterol f...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters